Top

European Journal of Nutrition

Published in:

01-08-2018 | Original Contribution

Dietary eicosapentaenoic acid normalizes hippocampal omega-3 and 6 polyunsaturated fatty acid profile, attenuates glial activation and regulates BDNF function in a rodent model of neuroinflammation induced by central interleukin-1β administration

Authors: Yilong Dong, Min Xu, Allan V. Kalueff, Cai Song

Published in: European Journal of Nutrition | Issue 5/2018

Abstract

Purpose

Interleukin (IL)-1β can activate glial cells to trigger neuroinflammation and neurodegeneration. Lower omega (n)-3 polyunsaturated fatty acids (PUFAs) and lower n-3/n-6 PUFA ratios occur in the brain of patients with Alzheimer’s disease (AD). We have previously reported that an n-3 PUFA, eicosapentaenoic acid (EPA), can improve memory and attenuate neurodegeneration-like changes in animal models of AD. However, whether and how EPA modulates glial cell activity and functions remains unclear. The aim of this study was to test the hypothesis that EPA may attenuate neuroinflammation by inhibiting microglial activation and microglia-produced proinflammatory cytokines, and by enhancing the expression of astrocytes-produced neurotrophins and their receptors.

Methods

Male Long-Evans rats were fed either palm oil supplemented diet or EPA supplemented diet for 42 days. On day 36 of diet feeding, rats received an intracerebroventricular injection of IL-1β or saline for 7 days. The glial activation, the expression of amyloid precursor protein (APP), calcium-dependent phospholipase (cPL) A2, brain-derived neurotrophic factor (BDNF) and its receptor, and PUFA profile in the hippocampus were analyzed.

Results

IL-1β elevated biomarkers of microglial CD11b and astrocyte GFAP expression, increased the expression of APP, tumor-necrosis factor (TNF)-α, but reduced BDNF and its receptor (TrKB). IL-1β also lowered n-3 EPA and docosapentaenoic acid concentrations but increased n-6 PUFAs and cPLA2 activity in the hippocampus. EPA supplement normalized the n-3 and n-6 PUFA profiles and cPLA2 levels, inhibited glial activation, reduced APP and TNF-α expression, as well as up-regulated BDNF and TrKB.

Conclusion

Supplementation with EPA appear to have potential effects on improving glial over-activation, n3/n6 imbalance and BDNF down-regulation, which contribute to anti-inflammatory and may provide beneficial effects on inflammation-associated disease such as AD.

Esiri MM (2007) The interplay between inflammation and neurodegeneration in CNS disease. J Neuroimmunol 184(1–2):4–16. doi:10.1016/j.jneuroim.2006.11.013 CrossRefPubMed

Mrak RE, Griffin WST (2005) Glia and their cytokines in progression of neurodegeneration. Neurobiol Aging 26(3):349–354. doi:10.1016/jneurobiolaging.2004.05.010 CrossRefPubMed

Finch CE, Morgan TE (2007) Systemic inflammation, infection, ApoE alleles, and Alzheimer disease: a positionpaper. Curr Alzheimer Res 4(2):185–189CrossRefPubMed

Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, Jacobs AH, Wyss-Coray T, Vitorica J, Ransohoff RM, Herrup K, Frautschy SA, Finsen B, Brown GC, Verkhratsky A, Yamanaka K, Koistinaho J, Latz E, Halle A, Petzold GC, Town T, Morgan D, Shinohara ML, Perry VH, Holmes C, Bazan NG, Brooks DJ, Hunot S, Joseph B, Deigendesch N, Garaschuk O, Boddeke E, Dinarello CA, Breitner JC, Cole GM, Golenbock DT, Kummer MP (2015) Neuroinflammation in Alzheimer’s disease. Lancet Neurol 14(4):388–405. doi:10.1016/S1474-4422(15)70016-5 CrossRefPubMedPubMedCentral

Kitazawa M, Cheng D, Tsukamoto MR, Koike MA, Wes PD, Vasilevko V, Cribbs DH, LaFerla FM (2011) Blocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal β-catenin pathway function in an Alzheimer’s disease model. J Immunol 187(12):6539–6549. doi:10.4049/jimmunol.1100620 CrossRefPubMedPubMedCentral

Song C, Zhang Y, Dong Y (2013) Acute and subacute IL-1β administrations differentially modulate neuroimmune and neurotrophic systems: possible implications for neuroprotection and neurodegeneration. J Neuroinflammation 10:59. doi:10.1186/1742-2094-10-59 CrossRefPubMedPubMedCentral

Min SK, Park JS, Luo L, Kwon YS, Lee HC, Shim HJ, Kim ID, Lee JK, Shin HS (2015) Assessment of C-phycocyanin effect on astrocytes-mediated neuroprotection against oxidative brain injury using 2D and 3D astrocyte tissue model. Sci Rep 5:14418. doi:10.1038/srep14418 CrossRefPubMedPubMedCentral

Lee J, Fukumoto H, Orne J, Klucken J, Raju S, Vanderburg CR, Irizarry MC, Hyman BT, Ingelsson M (2005) Decreased levels of BDNF protein in Alzheimer temporal cortex are independent of BDNF polymorphisms. Exp Neurol 194(1):91–96. doi:10.1016/j.expneurol.2005.01.026 CrossRefPubMed

Laske C, Stransky E, Leyhe T, Eschweiler GW, Wittorf A, Richartz E, Bartels M, Buchkremer G, Schott K (2006) Stage dependent BDNF serum concentrations in Alzheimer’s disease. J Neural Transm 113(9):1217–1224. doi:10.1007/s00702-005-0397-y CrossRefPubMed

10.

Bovolenta R, Zucchini S, Paradiso B, Rodi D, Merigo F, Navarro Mora G, Osculati F, Berto E, Marconi P, Marzola A, Fabene PF, Simonato M (2010) Hippocampal FGF-2 and BDNF overexpression attenuates epileptogenesis-associated neuroinflammation and reduces spontaneous recurrent seizures. J Neuroinflammation 7:81. doi:10.1186/1742-2094-7-81 CrossRefPubMedPubMedCentral

11.

Jiang Y, Wei N, Lu T, Zhu J, Xu G, Liu X (2011) Intranasal brain-derived neurotrophic factor protects brain from ischemic insult via modulating local inflammation in rats. Neuroscience 172:398–405. doi:10.1016/jneuroscience.2010.10.054 CrossRefPubMed

12.

Al-Amin MM, Reza HM (2014) Neuroinflammation: contemporary anti-inflammatory treatment approaches. Neurosciences (Riyadh) 19(2):87–92

13.

Song C, Li X, Leonard BE, Horrobin DF (2003) Effects of dietary n-3 or n-6 fatty acids on interleukin-1beta-induced anxiety, stress, and inflammatory responses in rats. J Lipid Res 44(10):1984–1991. doi:10.1194/jlr.M300217-JLR200 CrossRefPubMed

14.

Song C, Horrobin D (2004) Omega-3 fatty acid ethyl-eicosapentaenoate, but not soybean oil, attenuates memory impairment induced by central IL-1beta administration. J Lipid Res 45(6):1112–1121. doi:10.1194/jlr.M300526-JLR200 CrossRefPubMed

15.

Song C, Manku MS, Horrobin DF (2008) Long-chain polyunsaturated fatty acids modulate interleukin-1beta-induced changes in behavior, monoaminergic neurotransmitters, and brain inflammation in rats. J Nutr 138(5):954–963CrossRefPubMed

16.

Horrobin DF, Bennett CN (1999) Depression and bipolar disorder: relationships to impaired fatty acid and phospholipid metabolism and to diabetes, cardiovascular disease, immunological abnormalities, cancer, ageing and osteoporosis. Possible candidate genes. Prostaglandins Leukot Essent Fatty Acids 60(4):217–234. doi:10.1054/plef.1999.0037 CrossRefPubMed

17.

Russo GL (2009) Dietary n-6 and n-3 polyunsaturated fatty acids: from biochemistry to clinical implications in cardiovascular prevention. Biochem Pharmacol 77(6):937–946. doi:10.1016/j.bcp.2008.10.020 CrossRefPubMed

18.

Lone AM, Taskén K (2013) Proinflammatory and immunoregulatory roles of eicosanoids in T cells. Front Immunol 4:130. doi:10.3389/fimmu.2013.00130 CrossRefPubMedPubMedCentral

19.

Bernardo A, Minghetti L (2006) PPAR-gamma agonists as regulators of microglial activation and brain inflammation. Curr Pharm 12(1):93–109CrossRef

20.

Fernández-Fernández L, Comes G, Bolea I, Valente T, Ruiz J, Murtra P, Ramirez B, Anglés N, Reguant J, Morelló JR, Boada M, Hidalgo J, Escorihuela RM, Unzeta M (2012) LMN diet, rich in polyphenols and polyunsaturated fatty acids, improves mouse cognitive decline associated with aging and Alzheimer’s disease. Behav Brain Res 228:261–271. doi:10.1016/j.bbr.2011.11.014 CrossRefPubMed

21.

Hashimoto M, Hossain S (2011) Neuroprotective and ameliorative actions of polyunsaturated fatty acids against neuronal diseases: beneficial effect of docosahexaenoic acid on cognitive decline in Alzheimer’s disease. Pharmacol Sci 116(2):150–162CrossRef

22.

Horrobin DF (2002) A new category of psychotropic drugs: neuroactive lipids as exemplified by ethyl eicosapentaenoate (E-E). Prog Drug Res 59:171–199CrossRefPubMed

23.

Peet M, Stokes C (2005) Omega-3 fatty acids in the treatment of psychiatric disorders. Drugs 65(8):1051–1059CrossRefPubMed

24.

Taepavarapruk P, Song C (2010) Reductions of acetylcholine release and nerve growth factor expression are correlated with memory impairment induced by interleukin-1beta administrations: effects of omega-3 fatty acid EPA treatment. J Neurochem 112(4):1054–1064. doi:10.1111/j.1471-4159.2009.06524.x CrossRefPubMed

25.

Zhou WW, Lu S, Su YJ, Xue D, Yu XL, Wang SW, Zhang H, Xu PX, Xie XX, Liu RT (2014) Decreasing oxidative stress and neuroinflammation with a multifunctional peptide rescues memory deficits in mice with Alzheimer disease. Free Radic Biol Med 74:50–63. doi:10.1016/j.freeradbiomed.2014.06.013 CrossRefPubMed

26.

Meng Q, Luchtman DW, El Bahh B, Zidichouski JA, Yang J, Song C (2010) Ethyl-eicosapentaenoate modulates changes in neurochemistry and brain lipids induced by parkinsonian neurotoxin 1-methyl-4-phenylpyridinium in mouse brain slices. Eur J Pharmacol 649(1–3):127–134. doi:10.1016/j.ejphar.2010.09.046 CrossRefPubMed

27.

Song C, Li X, Kang Z, Kadotomi Y (2007) Omega-3 fatty acid ethyl-eicosapentaenoate attenuates IL-1beta-induced changes in dopamine and metabolites in the shell of the nucleus accumbens: involved with PLA2 activity and corticosterone secretion. Neuropsychopharmacology 32(3):736–744. doi:10.1038/sj.npp.1301117 CrossRefPubMed

28.

Qian L, Hong JS, Flood PM (2006) Role of microglia in inflammation-mediated degeneration of dopaminergic neurons: neuroprotective effect of interleukin 10. J Neural Transm Suppl 70:367–371CrossRef

29.

Colombo E, Cordiglieri C, Melli G, Newcombe J, Krumbholz M, Parada LF, Medico E, Hohlfeld R, Meinl E, Farina C (2012) Stimulation of the neurotrophin receptor TrkB on astrocytes drives nitric oxide production and neurodegeneration. J Exp Med 209(3):521–535. doi:10.1084/jem.20110698 CrossRefPubMedPubMedCentral

30.

Capsoni S, Brandi R, Arisi I, D’Onofrio M, Cattaneo A (2011) A dual mechanism linking NGF/proNGF imbalance and early inflammation to Alzheimer’s disease neurodegeneration in the AD11 anti-NGF mouse model. CNS Neurol Disord Drug Targets 10(5):635–647CrossRefPubMed

31.

Huang EJ, Reichardt LF (2003) Trk receptors: roles in neuronal signal transduction. Annu Rev Biochem 72:609–642. doi:10.1146/annurev.biochem.72.121801.161629 CrossRefPubMed

32.

Bibel M, Barde YA (2000) Neurotrophins: key regulators of cell fate and cell shape in the vertebrate nervous system. Genes Dev 14(23):2919–2937CrossRefPubMed

33.

Mamidipudi V, Wooten MW (2002) Dual Role for p75NTR signaling in survival and cell death: can intracellular mediators provide and explanation? J Neurosci 68(4):373–384. doi:10.1002/jnr.10244 CrossRef

34.

Madani S, Hichami A, Legrand A, Belleville J, Khan NA (2001) Implication of acyl chain of diacylglycerols in activation of different isoforms of protein kinase C. FASEB J 15(14):2595–2601. doi:10.1096/fj.01-0753int CrossRefPubMed

35.

Lee JG, Cho HY, Park SW, Seo MK, Kim YH (2010) Effects of olanzapine on brain-derived neurotrophic factor gene promoter activity in SH-SY5Y neuroblastoma cells. Prog Neuropsychopharmacol Biol Psychiatry 34(6):1001–1006. doi:10.1016/j.pnpbp.2010.05.013 CrossRefPubMed

36.

Parazzoli S, Harmon JS, Vallerie SN, Zhang T, Zhou H, Robertson RP (2012) Cyclooxygenase-2, not microsomal prostaglandin E synthase-1, is the mechanism for interleukin-1β-induced prostaglandin E2 production and inhibition of insulin secretion in pancreatic islets. J Biol Chem 287(38):32246–32253. doi:10.1074/jbc.M112.364612 CrossRefPubMedPubMedCentral

37.

Tanikawa M, Lee HY, Watanabe K, Majewska M, Skarzynski DJ, Park SB, Lee DS, Park CK, Acosta TJ, Okuda K (2008) Regulation of prostaglandin biosynthesis by interleukin-1 in cultured bovine endometrial cells. J Endocrinol 199(3):425–434. doi:10.1677/JOE-08-0237 CrossRefPubMed

38.

Sanchez-Mejia RO,Mucke L (2010) Phospholipase A2 and arachidonic acid in Alzheimer’s disease. Biochim Biophys Acta. Biochim Biophys Acta 1801(8):784–790. doi:10.1016/j.bbalip.2010.05.013 CrossRef

39.

Willis S, Samala R, Rosenberger TA, Borges K (2009) Eicosapentaenoic and docosahexaenoic acids are not anticonvulsant or neuroprotective in acute mouse seizure models. Epilepsia 50(1):138–142. doi:10.1111/j.1528-1167.2008.01722.x CrossRefPubMed

40.

Igarashi M, DeMar JC Jr, Ma K, Chang L, Bell JM, Rapoport SI (2007) Docosahexaenoic acid synthesis from alpha-linolenic acid by rat brain is unaffected by dietary n-3 PUFA deprivation. J Lipid Res 48(5):1150–1158. doi:10.1194/jlr.M600549-JLR200 CrossRefPubMed

41.

Bourre JM, Dumont OS, Piciotti MJ, Pascal GA, Gurand GA (1992) Dietary alpha-linolenic acid deficiency in adult rats for 7 months does not alter brain docosahexaenoic acid content, in contrast to liver, heart and testes. Biochim Biophys Acta 1124(2):119–122CrossRefPubMed

42.

Siegert E, Paul F, Rothe M, Weylandt KH (2017) The effect of omega-3 fatty acids on central nervous system remyelination in fat-1 mice. BMC Neurosci 18(1):19. doi:10.1186/s12868-016-0312-5 CrossRefPubMedPubMedCentral

Title: Dietary eicosapentaenoic acid normalizes hippocampal omega-3 and 6 polyunsaturated fatty acid profile, attenuates glial activation and regulates BDNF function in a rodent model of neuroinflammation induced by central interleukin-1β administration
Authors: Yilong Dong
Min Xu
Allan V. Kalueff
Cai Song
Publication date: 01-08-2018
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nutrition / Issue 5/2018
Print ISSN: 1436-6207
Electronic ISSN: 1436-6215
DOI: https://doi.org/10.1007/s00394-017-1462-7

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Dietary eicosapentaenoic acid normalizes hippocampal omega-3 and 6 polyunsaturated fatty acid profile, attenuates glial activation and regulates BDNF function in a rodent model of neuroinflammation induced by central interleukin-1β administration

Abstract

Purpose

Methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2018

Comparison of urinary iodine levels in women of childbearing age during and after pregnancy

Oxidative damage of mitochondrial respiratory chain in different organs of a rat model of diet-induced obesity

A comparison of principal component analysis, partial least-squares and reduced-rank regressions in the identification of dietary patterns associated with bone mass in ageing Australians

SEPP1 polymorphisms modulate serum glucose and lipid response to Brazil nut supplementation

Polyphenolic extract attenuates fatty acid-induced steatosis and oxidative stress in hepatic and endothelial cells

Effect of GPR84 deletion on obesity and diabetes development in mice fed long chain or medium chain fatty acid rich diets

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page